Drug · Anti-CCR4
Mogamulizumab
Trade name: Poteligeo.
Mogamulizumab is a humanised anti-CCR4 monoclonal antibody. CCR4 is highly expressed on Sézary cells and on some mycosis fungoides cells. NICE-approved (TA754) for relapsed or refractory mycosis fungoides and Sézary syndrome after at least one prior systemic therapy.
CurrentLast reviewed 25 March 2026
Indications
- Relapsed or refractory mycosis fungoides / Sézary syndrome after at least one prior systemic therapy (NICE TA754).
Dosing
- 1 mg/kg IV on days 1, 8, 15 and 22 of cycle 1 (weekly × 4), then days 1 and 15 of each subsequent 28-day cycle (every 2 weeks) until disease progression or unacceptable toxicity (per MAVORIC schedule and UK SmPC).
Adverse events
- Infusion reactions (~30%) — premedicate.
- Mogamulizumab-associated rash (MAR) — occurs in ~25–30% of MF/SS patients; characteristically a psoriasiform or spongiotic eruption that mimics disease progression. Biopsy distinguishes — MAR may be associated with response in some series; do not discontinue mogamulizumab on suspicion of disease progression without histological confirmation.
- Cytopenias.
- Infections (CCR4 depletion of regulatory T-cells).
- Severe steroid-refractory acute graft-versus-host disease (GvHD) when mogamulizumab is given before allogeneic HSCT — FDA boxed warning; EMA / UK SmPC cautions are aligned. The mechanism is recipient regulatory-T-cell depletion. A pre-transplant washout of ≥ 50 days (some centres ≥ 90 days) is required; discuss timing with the transplant team well in advance of planned HSCT.
References
- Kim YH et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC). Lancet Oncol; 2018.
- NICE TA754. Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome. London: NICE; accessed 18 May 2026.
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.